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Abstract 
Background 
Some level of monitoring is usually required during a clinical trial to protect the rights and 
safety of trial participants and to safeguard the quality and reliability of trial results. Although 
there is increasing support for the use of risk-proportionate approaches to achieve these aims, 
the variety of methods and lack of an empirical evidence base can present challenges for 
clinical trial practitioners. 
Methods 
This paper describes the monitoring methods and procedures that are utilised by a non-
commercial clinical trials unit which coordinates a range of clinical trials across a variety of 
clinical areas with different associated risks. 
Results 
Monitoring activities and approaches should be selected to be proportionate to the risks 
identified within a trial. A risk-proportionate approach to monitoring is described giving 
details of methods that may be considered by clinical trial practitioners during the 
development of a trial monitoring plan. An example risk assessment and corresponding 
monitoring plan for a low risk (type A in the Medicines and Healthcare Products Regulatory 
Agency (MHRA) classification system) pediatric trial is provided for illustration. 
Conclusion 
We present ideas for developing a monitoring plan for a clinical trial of an investigational 
medicinal product based on our experience. Alternative approaches may be relevant or 
preferable in other settings based on inherent risk. 
Keywords 
Monitoring, Central monitoring, On-site monitoring, Risk proportionate, Quality assurance 
Background 
Trial monitoring is defined by the International Conference on Harmonisation of Good 
Clinical Practice (ICH GCP) as ‘the act of overseeing the progress of a clinical trial and of 
ensuring that it is conducted, recorded and reported in accordance with the protocol, Standard 
Operating Procedures (SOPs), Good Clinical Practice (GCP), and the applicable regulatory 
requirement(s)’ [1]. ICH GCP also states that ‘the purposes of trial monitoring are to verify 
that: (a) the rights and well-being of human subjects are protected, (b) the reported trial data 
are accurate, complete, and verifiable from source documents, (c) the conduct of the trial is in 
compliance with the currently approved protocol / amendment(s), with GCP and with the 
applicable regulatory requirement(s)’ [1]. 
The ICH GCP guidance is not specific about which methods should be used but suggests that 
‘the extent and nature of monitoring should be based on considerations such as the objective, 
purpose, design, complexity, blinding, size and endpoints of the trial’ [1]. The guidance 
highlights a general need for on-site monitoring during different phases of the trial, but 
recognizes that ‘in exceptional circumstances the sponsor may determine that central 
monitoring in conjunction with procedures such as investigators’ training and meetings, and 
extensive written guidance can assure appropriate conduct of the trial in accordance with 
GCP’ [1]. However, this has been criticized in the literature, with concerns raised that 
inefficient methods of monitoring are being used unnecessarily in some trials due to 
misinterpretation of the guidance [2] and a misconception that on-site monitoring is a legal 
requirement. This has in part led to recent initiatives on risk-adapted approaches to 
monitoring from the Clinical Trials Transformation Initiative (CTTI) [3], Department of 
Health [4], Food and Drug Administration (FDA) [5], and the European Medicines Agency 
(EMA) [6]. These are substantial developments, both for commercial and non-commercial 
clinical trials, and will provide the potential to reduce costs and increase efficiency. However, 
there is a lack of empirical evidence to determine which practices best achieve the goals of 
monitoring stated in ICH GCP [3] and, consequently, heterogeneity in methods of monitoring 
[7]. Although some empirical evidence is emerging in the literature [8-11], there are very few 
published examples of monitoring methods that are used in practice, which limits the 
potential for the sharing of practical experience and expertise to assist clinical trial 
practitioners developing monitoring procedures to use in practice. The aim of this paper is to 
describe the risk-proportionate approach to monitoring, with details of central monitoring as 
well as on-site monitoring methods, currently undertaken at the Clinical Trials Research 
Centre (CTRC), University of Liverpool, to improve access to, and encourage sharing of 
practical methods. 
Methods/Design 
Risk-proportionate approach to monitoring adopted at the Clinical Trials 
Research Centre (CTRC) 
The CTRC, based at the University of Liverpool, UK, was established in 2007 and gained full 
registration status as a United Kingdom Clinical Research Collaboration (UKCRC) clinical 
trials unit in 2009. The UKCRC has a network of 45 registered Clinical Trials Units (CTUs) 
which have provided evidence to an international panel of experts of their capability to 
coordinate multi-centre clinical trials (having overall responsibility for the design, 
development, recruitment, data management, publicity and analysis of a portfolio of trials), 
and of robust systems to ensure the conduct and delivery of clinical trials to the highest 
quality standards. The portfolio of trials that are designed, coordinated and analyzed at the 
CTRC include pediatric, obstetrics and gynecology, neurology, infection, and dental trials 
involving investigational medicinal products, devices, and surgical techniques. The trials vary 
considerably in target sample size, the number of recruiting sites, length of follow up, and 
experience of research staff at recruiting sites, but all trials would adopt a risk-proportionate 
approach to monitoring as described in this manuscript. 
In terms of the potential risk associated with the Investigational Medicinal Product (IMP), the 
majority of trials coordinated by the CTRC would be categorized as ‘Type A’ (no higher than 
the risk of standard medical care) or ‘Type B’ (somewhat higher than the risk of standard 
medical care) according to the MRC/DH/MHRA Joint Project guidance on Risk-adapted 
Approaches to the Management of Clinical Trials of Investigational Medicinal Products [4]. 
Each trial has three oversight committees: the Trial Management Group (TMG) concerned 
with day to day running of the trial, the Independent Data and Safety Monitoring Committee 
(IDSMC) to view trial arm comparisons of safety and effectiveness, and the Trial Steering 
Committee (TSC) that considers the recommendations of the IDSMC and makes the ultimate 
decision for the continuation of the trial. A separate charter is developed to describe the 
membership, planned frequency of meetings, roles and responsibilities, and interactions 
between these committees, which would be referenced within the monitoring plan. 
The stages involved in the risk proportionate approach to monitoring adopted by the CTRC 
are briefly summarized in Figure 1. For each trial, a structured risk assessment is undertaken 
to identify potential patient, study or organizational hazards (see example risk assessment in 
Additional file 1). 
Figure 1 Risk proportionate approach to monitoring at CTRC. 
This requires input from the multi-disciplinary trial team, including statistics, data 
management, trial management and clinical input. The CTRC Operational Team reviews all 
CTRC Risk Assessments and final approval of each completed risk assessment is obtained 
from the CTRC Director, Sponsor and Chief Investigator. The risk assessment form contains 
both generic and specific hazards and for each hazard it should be documented whether that 
hazard is, or is not, applicable to the trial. Any additional trial specific hazards should be 
added to the risk assessment. The total, mean, and overall percentage risk scores are 
calculated for the trial (using formulae described in Additional file 1) to provide an overall 
guide and trial risk classification. However, individual risk scores should also be examined 
closely (using the risk management matrix and key in Additional file 1) to ensure that 
appropriate strategies are in place for monitoring hazards with particularly high risk scores. 
The allocation of scores can be subjective and alternative approaches to risk assessment, 
which do not require the calculation of a numerical score, may be appropriate. 
The extent and nature of the monitoring required is determined by the risk mitigating 
activities to be undertaken and specified within the monitoring plan (example in Additional 
file 2) with specification of escalation of monitoring activities. The aim of the monitoring 
plan is to describe how problems that could affect the rights and safety of participants or the 
reliability of study results can be prevented, or detected in a timely fashion through 
appropriate monitoring and subsequent corrective action. Regular trial monitoring reports () 
are produced and used to determine when action such as additional site training or on-site 
visits are required as specified in the monitoring plan. For ‘Type A’ classified trials the 
monitoring plan would usually describe mostly centralised procedures with triggered on-site 
visits and would highlight examples of triggers for further action. The risk assessment and 
monitoring plan may be revised in light of protocol amendments or monitoring reports. 
Developing the monitoring plan 
The CTRC monitoring plan is a document which describes all monitoring activities for a 
particular trial and details planned central monitoring, on-site monitoring, oversight 
committees, the roles and responsibilities for undertaking activities, and relevant timelines. 
The plan would also be developed with appropriate consideration for the size of the trial as 
some monitoring methods may be restricted for small trials. Examples of monitoring 
activities that would be included within the monitoring plan are described in the following 
sections. An illustrative example is provided in Additional file 2 which relates to a pediatric 
CTRC ‘Type A’ Trial of Optimal TheRapy for Pseudomonas EraDicatiOn in Cystic Fibrosis 
(TORPEDO-CF). The summary protocol and corresponding risk assessment are also 
provided (Additional files 1 and 3). 
Responsibilities 
The Sponsor has ‘ultimate responsibility for the quality and integrity of the trial data’ [1] but 
may delegate activities whilst maintaining appropriate oversight. The multidisciplinary nature 
of the TMG and the multilevel nature of monitoring approaches demand the need for 
individual responsibilities and expectations to be clearly defined within the monitoring plan. 
The CTRC monitoring plan development team includes the Trial Coordinator (TC), Trial 
Statistician (TS), Trial Monitor (TM) (if relevant) and Chief Investigator (CI) of the trial. 
This development team structure is regarded as the minimum requirement with input sought 
from additional expert members, such as a pharmacist, where specific hazards have been 
identified. The TC takes overall responsibility for coordinating the production of the 
monitoring report . The CTRC Senior Management Team (SMT), which consists of the 
CTRC Director, Head of Statistics, Head of Trial management, Head of Information Systems, 
Quality Assurance Manager, and Head of Data Management, review and sign off the 
monitoring plan for each trial before implementation. 
Results and discussion 
Trial monitoring approaches 
There are essentially two approaches for monitoring clinical trials: central monitoring, and 
on-site monitoring, with the monitoring plan providing a summary of the practical procedures 
and reporting summaries required to undertake these activities. 
Central monitoring 
Central monitoring involves centralized procedures for the quality control of trial data. 
Responsibility for each section of the monitoring report should be specified within the 
monitoring plan. There are numerous central monitoring procedures that may be considered 
for an individual trial. Some approaches involve using statistical methods (central statistical 
monitoring) to explore patterns in the accumulating data, some involve monitoring results of 
automated validation checks that may be built into the data management facility, some may 
involve the central review of forms submitted to the CTRC, and some may involve a 
comparison of performance across participating sites. Defining an ‘acceptability threshold’, 
such that the crossing of this threshold would trigger action, may also be helpful to guide 
decision making for some monitoring activities (for example see Section ‘missing primary 
outcome data’) These central monitoring methods are used to assure the quality and 
reliability of trial data, protect the safety of trial participants, detect trial conduct problems at 
particular sites, and can be useful for detecting fraud [12]. Listed below and in Additional file 
2 are examples of central monitoring procedures that would usually be considered for CTRC 
trials, although it is recognized that this is not an exhaustive list. 
Review of consent forms 
Documenting that the consent process has taken place and that trial participants have been 
fully informed about the trial is an essential process to safeguard the rights of trial 
participants. In general, copies of completed consent forms are faxed to the CTRC within 
seven days of completion by participating sites. Each form is then checked using a consent 
form checklist to ensure that each form has been fully and accurately completed and returned 
from sites within a reasonable time frame. Any issues identified through this routine review 
of consent forms is summarized in the trial monitoring report to enable the overall site 
specific issues to be reviewed. As patient signatures are included on completed consent 
forms, all faxed copies are kept securely in a locked cabinet, separate from other trial 
documents. Patient names are not routinely recorded or linked in any way with further data 
which may be collected during the trial. Furthermore, the patient consent form explicitly 
requests permission for the completed consent form to be passed to the CTRC for the 
administration of the study. 
Checks across individual sites for problems 
In multi-centre trials, data from one site can be compared with data for the whole trial to 
compare performance and identify patterns which may indicate that action is required. The 
key data items to be compared across sites should be identified after consideration of the risk 
assessment and listed in the monitoring plan. Methods for statistical monitoring such as 
exploring digit preference, rounding, or unusual features of a frequency distribution (such as 
outliers, inliers, or atypical degrees of skewness or kurtosis) which have been described [2] 
for the detection of data fabrication or data falsification, may be useful when considering the 
comparison of data across sites. Graphical approaches such as site-specific box and whisker 
plots of key continuous variables, or graphical approaches described in later sections, can 
help with interpretation of site comparisons and facilitate decision making. However, it 
should be noted that differences in participant characteristics across sites may explain 
apparent differences for certain types of variables. Furthermore, the application of some 
methods for statistical monitoring are limited in small trials and the issue of multiple testing 
needs to be considered carefully if significance tests are to be performed. 
Recruitment and retention 
Recruitment of participants below the expected or predicted recruitment rates can jeopardise 
the power of the study, impose time delays and financial penalties on the trial, and can lead to 
premature trial closure. Frequent monitoring of recruitment data will help to identify whether 
the target sample size can be achieved within the expected timeframe, and any appropriate 
corrective action that may be required. 
The frequency of non-eligible patients and eligible patients who do not provide consent (with 
a summary of the reasons) compared across sites can give valuable information about the 
recruitment process, including restrictive eligibility criteria or issues in its application or 
interpretation. Comparison of site specific retention rates (percentage of patients at a site that 
have withdrawn) can highlight sites where there may be issues with following the correct 
consent process. 
The benefits of monitoring recruitment by site include identification of sites which are 
recruiting well to determine successful recruitment initiatives relevant to other sites, 
additional site-specific support can be provided for poor recruiting sites or poor recruiting 
sites can be closed and resources redistributed appropriately. Early identification is essential 
to allow adequate time for planning additional trial-specific and site specific resources. An 
example graph showing overall recruitment and site openings is presented in Figure 2. 
Similar site specific graphs or graphs showing site specific recruitment rates per unit of time 
can also provide valuable information. 
Figure 2 Overall recruitment graph. 
Randomization system 
Adequately concealed randomization systems eliminate selection bias and produce groups of 
participants that are balanced with respect to known and unknown prognostic factors. All 
randomized trials should be monitored to ensure that the randomization system is working 
correctly and that participants are being randomized properly. These checks would be 
undertaken by the TS and would usually coincide with the preparation of data monitoring 
reports presented to the IDSMC. However, a minimum check should be scheduled during 
early stages of recruitment to promptly identify problems and apply corrective action. The 
risk assessment may indicate that more frequent monitoring is required if, for example, 
randomization envelopes or a web-based minimisation procedure are being utilised. The 
appropriate checks to undertake will depend on the method of randomization but would 
include a summary of baseline characteristics and number randomized between treatment 
groups (usually presented in the IDSMC report), as an imbalance could indicate a problem 
with the randomization system. If stratification has been used in the randomization process 
the number randomized in each treatment group across stratification variables should be 
summarized. Depending on the implications for unblinding, details of such randomization 
checks may not be included in the trial monitoring report beyond stating that the check was 
conducted with results held confidentially by the trial statistics team. In addition, the 
randomization numbers should be checked to ensure that they have been allocated in 
chronological order with any missing randomization number accounted for with appropriate 
explanation. The correct implementation of the randomization process at sites is crucial. Any 
site specific randomization problems should therefore be summarized in the trial monitoring 
report with only a minimum number of errors required to trigger further action. 
Missing primary outcome data 
Missing primary outcome data can affect the reliability of trial results, particularly when there 
is a substantial amount of missing data or if reasons for missing data are related to treatment 
or outcome. Procedures to minimise the occurrence of missing data should always be 
considered and incorporated into the trial design, and repeatedly highlighted to staff 
throughout the trial. To allow for the potential impact on power it is usual practice to inflate 
the estimated sample size to allow for a certain percentage of missing data. This inflation 
factor may be a reasonable upper value to define an acceptability threshold for missing 
primary outcome data to guide decision making and appropriate further action during 
monitoring activities. The cumulative percentage of participants with missing primary 
outcome at each site can be plotted (Figure 3) at various time-points, which need not 
necessarily be equally spaced. This graphical approach can facilitate interpretation and help 
easily identify sites which cross the acceptability threshold (5 % is used in Figure 3), or 
which repeatedly remain at an unacceptably high level. The reason for missing primary 
outcome data should be identified and summarized along with the graph. Any missing 
primary outcome data should be routinely queried with the site as soon as possible. If the 
cumulative percentage of participants with missing primary outcome data crosses the 
acceptability threshold the site should be contacted to discuss and reiterate the importance of 
complete data for this outcome. A subsequent site visit should be arranged if the problem is 
still apparent in the next trial monitoring report. 
Figure 3 Example of acceptability threshold graph for missing primary outcome data. 
Patient safety 
The pharmacovigilance plan is specified in the protocol and considered appropriate to the 
risks identified in the trial and what is known about the interventions and conditions under 
study [13,14]. The IDSMC is responsible for monitoring patient safety throughout the trial 
and this would usually be done through a regular review of accumulating data. The trial 
monitoring plan would usually include details of safety reporting indicators (identified from 
the risk assessment) that are compared across sites to identify whether events are being 
identified and reported consistently, and in a timely manner. Example graphical approaches 
for comparing safety reporting indicators are provided in Figure 4 (hypothetical data used for 
illustrative purposes only) where the key data item of interest is serious adverse events 
(SAEs). 
Figure 4 Example graphical approaches (hypothetical data) for comparing serious 
adverse events (SAEs). (a) percentage participants with at least one SAE, (b) discrepancy in 
SAE event, (c) SAE rate at site 1. 
In Figure 4a, the cumulative percentage of participants with at least one event across the trial 
as a whole, and at each site, are plotted together against some measure of time (month in this 
example) which need not be equally spaced. This can be used to check for under or over 
reporting of SAEs at sites, and is a useful approach if a small number of events of this 
particular type (SAEs in this example) are expected, and most likely to occur infrequently per 
participant. Large discrepancies can be discussed and monitored closely over time to identify 
whether any patterns persist which may trigger further action. 
The approach in Figure 4a does not account for the length of follow-up of each individual 
participant. If there is variability in participants’ length of follow-up and follow-up time is 
expected to increase the likelihood of an event such as an SAE, the approach summarized in 
Figure 4b may be preferable. Here, the overall event rate for the trial (sum of all events 
divided by the sum of all follow-up for the trial) is calculated, along with the expected 
number of events per site (sum of all follow up at a site x overall event rate for the trial). The 
difference between the actual and expected number of events at each site is plotted against 
time (Figure 4b). 
If the event of interest is expected to occur frequently with multiple events per participant, 
such as SAEs in a cancer trial, the plot in Figure 4c may be most appropriate. Here the overall 
mean number of SAEs per participant per unit time (such as month) is calculated across all 
sites (sum of all SAEs divided by the sum of all follow-up) with a reference range (for 
example a 95 % reference range = mean ± 1.96 x sd, where sd = √mean). It may be necessary 
to use a narrower reference range for early monitoring, or perhaps plot a 95 % and 90 % 
reference range on the same graph. The number of SAEs per unit time for each individual 
participant (sum of all SAEs for participant j divided by the sum of all follow-up for 
participant j) is plotted along with the overall mean number and reference range. This may be 
presented on a single plot highlighting outliers (with different symbol for each site) above or 
below the reference range or as site specific graphs comparing the distribution of events. The 
site specific percentage of participants with SAE rate outside the reference range can also be 
calculated (or plotted over time) to guide interpretation. The trial monitoring plan should 
specify guidelines to follow to determine appropriate action if the SAE rate crosses a 
particular threshold (such as upper and lower limits of the reference range). 
Protocol deviations 
Key protocol deviations that might occur during the trial should be identified by the TMG (in 
conjunction with the risk assessment) and summarized in the trial monitoring plan. The 
TORPEDO-CF monitoring plan (Additional file 2) provides an example of a protocol 
deviation table, listing examples of potential deviations of important protocol specifications 
such as eligibility criteria, treatment regimens and study assessments. For each item, the 
potential protocol deviations that may occur are listed and graded in terms of the impact such 
a deviation would have on patient safety and the reliability of trial results. This is generally 
graded as major (potentially major impact either through introduction of bias to study results 
or effect on safety) or minor (potentially minor impact on patient and not likely to introduce 
bias), but the grade may vary according to the degree of deviation observed. Justification is 
also provided for the assessment of the impact of each potential protocol deviation. All 
protocol deviations that occur during the trial should be summarized within the trial 
monitoring reports with particular focus on major deviations. If a particular deviation occurs 
frequently this may indicate the need for a protocol amendment. The graphical approaches 
described in Figure 3 and Figure 4 may be appropriate for the comparison of protocol 
deviation rate to identify sites which have more frequent deviations from protocol thereby 
requiring further training or on-site visits. 
Case report form (CRF) completion monitoring 
Paper CRFs are routinely checked (manually or electronically) when received to ensure that 
they are signed by authorised personnel. An electronic CRF tracking form keeps a record of 
CRFs received into the unit. Full details of the CRF tracking system should be included in the 
data management plan. A summary of data from the CRF tracking system, in particular 
missing CRFs, delay submitting CRFs (paper or electronic) to CTRC, completeness of 
reporting, and delay responding to queries can be generated by site or other alternative as 
appropriate. If an individual site consistently fails to keep up to date with CRF (paper or 
electronic) completion and timely submission to CTRC, the TC should work with the site to 
develop a plan to correct this issue. 
Validation of data 
Range and consistency checks can be used to identify unlikely or implausible data and would 
usually be programmed into the trial database of all CTRC trials during database 
development. All validation and consistency checks are recorded in the trial data 
management plan and referenced within the trial monitoring plan. External sources of 
information may also be available to check the validity of certain data variables. For example, 
date and cause of death can be verified by using death registry data such as that recorded by 
the Office of National Statistics in the UK. 
Visit dates, or other important dates can be routinely examined centrally to check for 
consistency and accuracy. For example, in some trials a weekend clinic visit would not be 
expected to occur and may indicate a data entry error or in some rare cases could suggest 
fraud. Visit date checks can also be used to identify visits which have occurred outside of 
protocol timelines or identify visits that have been missed. In larger trials it may be preferable 
to present site specific scatter plots of actual date of visit compared to expected date of visit 
and compare the percentage of visits outside the permitted visit window across sites. Finally, 
it is possible to identify inconsistent dates by cross checking different information within, and 
across CRFs for a patient. 
Summarising the results of range, consistency and validation checks across sites can provide 
useful information about compliance with the trial protocol and procedures, indicate resource 
issues at sites, and can be helpful supporting information when deciding whether site visits 
may be required. 
Pharmacy compliance with IMP handling procedures (clinical trials of IMPs 
only) 
Checks should be performed of the suitability of the environmental conditions (such as a 
central review of temperature logs), suitability of the product (expiry dates, potential 
degradation of the presentation) and checks that all medication can be accounted for via 
dispensing logs, checking that any medication returned by a participant matches the amount 
dispensed minus the amount consumed. 
Quality assurance of statistical analyses 
All interim and final statistical analyses are undertaken in accordance with the relevant 
standard operating procedures and statistical analysis plan. The derivation of the primary 
outcome, corresponding statistical analyses, and safety data are independently programmed 
by a CTRC statistician independent to the trial. These independent analyses are cross checked 
with those undertaken by the trial statistician. This is particularly important in trials which 
include a primary outcome with a complex definition that depends on multiple variables, 
requiring substantial programming. 
CTRC internal performance monitoring 
In addition to monitoring the performance of sites involved in the trial, it can often be 
important to monitor performance of the coordinating trials unit. One example would be to 
review the data entry process by comparing data entered by trials unit staff on the database 
against the data recorded on the paper CRF. This would usually be undertaken for all 
randomization related data and primary outcome data as a minimum with additional key data 
items identified as important from the risk assessment. These reviews are useful to (a) assure 
data accuracy, and (b) to identify whether data entry staff at the CTRC require further 
training or support. It may also be relevant to review other measures such as the time between 
receipt of paper CRF and completion of data entry, or number and type of queries raised, to 
allow potential delays in the system to be highlighted so that appropriate action can be taken 
as early as possible, minimising the negative impact on accumulating trial data. A summary 
of these internal performance reviews should be included in the trial monitoring report at the 
relevant time point, together with any required action plan. 
Other issues 
Other important hazards that require central monitoring should be identified from the risk 
assessment and appropriate procedures listed in the monitoring plan. For example, trials 
which rely on a blood test to guide treatment dosing would benefit from monitoring the 
number of invalid or missing blood samples across sites; trials using variable dosing of 
treatments may summarize dose (for example median, interquartile range, minimum and 
maximum) across sites which could identify inappropriate dosing that may have an impact on 
patient safety; in blinded trials the emergency unblinding rate should be compared across 
sites with appropriate measures in place to assure that the correct procedures have been 
followed. 
On-site monitoring 
On-site monitoring involves a member of the trial management team visiting an individual 
site to undertake monitoring activities. On-site monitoring may either be ‘routine’ in 
accordance with the monitoring plan, or may be ‘triggered’ as a result of the TMG review of 
trial monitoring reports. The rationale, timing, frequency and activities to be undertaken 
during routine on-site monitoring visits should be decided by the TMG in conjunction with 
the risk assessment, with appropriate consideration given to the rate of participant recruitment 
at each site, the complexity of trial procedures, and experience of the site in conducting 
clinical trials. 
If routine on-site monitoring is planned, the first site visit should ideally occur during the 
early phase of the trial following recruitment of the first few participants at the site to allow 
the monitor to pick up early issues, confirm accurate interpretation of the protocol and data 
management procedures, and address any unresolved queries or problems in a timely manner. 
Site visits will normally involve the Principal Investigator (PI) and site research 
nurse/practitioner but may involve any or all of the individuals involved with the trial at the 
particular site. This may include for example a research radiographer, trial pharmacist, or data 
manager at site. 
During routine site visits, focus would tend to be on making sure that trial procedures have 
been conducted in accordance with the trial protocol and according to the principles of GCP 
under the UK regulations. Any issues identified are discussed with site staff and explanations 
or remedial action documented within the site monitoring visit report which is sent to the site 
and also included in the TMG trial monitoring report. Routine on-site visits provide an 
opportunity for trial management staff to offer mentorship and additional training for site 
staff to ensure that procedures are being followed as outlined within the protocol. 
If the TMG review of trial monitoring reports identifies issues that cannot be resolved 
through contact with sites by email or telephone, or if significant issues are identified, a 
triggered site visit may be indicated. Examples of triggers might include: identification of 
clear differences between expected and actual recruitment rates, no recruitment for an 
extended period at site, identification of outlying screening failure rate at a particular site; 
missing primary outcome data above a pre-defined acceptability threshold; a higher or lower 
SAE reporting level at site in comparison with the trial as a whole that cannot be reasonably 
explained by knowledge of patient characteristics; repeated violations in the timing of 
consent and trial related procedures, repeated non-receipt of consent forms within the 
timelines specified in the protocol or inaccuracies in the completion of consent 
documentation; repeated use of superseded versions of the Patient Information Sheet and 
Consent forms (PISC); repeated evidence of protocol deviations (such as recruitment of 
ineligible participants); and repeated discrepancies in the assignment of randomization 
number at a given site. 
Following the triggered visit a site monitoring visit report will be completed detailing the 
reason for the visit, the processes reviewed, issues identified and discussed with the trial staff 
at the visit, as well as corrective measures to be implemented. The site monitoring visit report 
should be reviewed and signed by the monitor and PI on site and should be included in the 
trial monitoring reports for review by the TMG. A follow-up visit will be arranged with the 
site staff to ensure that any action points outlined in the site monitoring visit report have been 
acknowledged and rectified. 
The trial monitoring report 
The TMG are responsible for reviewing monitoring activities undertaken during the trial and 
for authorising the appropriate subsequent action to be undertaken. These activities are 
summarized in a trial monitoring report which is prepared by the Trial Coordinator (TC) with 
input from other team members as appropriate, and is reviewed according to a regular 
schedule which should be pre-specified in conjunction with the risk assessment and detailed 
in the monitoring plan. Higher risk trials, or fast recruiting trials, may require more frequent 
reviews of trial monitoring reports, and it may not always be necessary to present all 
monitoring activities in every trial monitoring report. For example, a trial experiencing 
recruitment difficulties may require additional TMG review of recruitment patterns and 
screening failure rates. The trial monitoring report discussed at these meetings would not 
necessarily require all pre-planned monitoring activities to be summarized. The frequency of 
review of trial monitoring reports may also need to be amended during the trial if issues that 
require immediate action are identified. 
The content of the trial monitoring reports will vary by trial but would generally include 
summary results of the central monitoring activities, statistical monitoring, issues raised from 
TSC and open IDSMC meetings, and on-site monitoring, with any relevant site monitoring 
visit reports included as an appendix to the report. 
To ensure that there is a record of any decisions made by the TMG, the trial monitoring 
report includes an 'actions' section listing all actions requested as a result of TMG review. 
This list of actions would also be included in the subsequent trial monitoring report for 
review by the TMG to ensure that all previous actions have been carried out with a 
satisfactory outcome. 
A site may be closed on the authority of the sponsor if they have not enrolled any participants 
for a considerable amount of time or the enrolment rate is not acceptable, or if the site is non-
compliant with trial procedures or regulatory requirements. During review of the trial 
monitoring report, the TMG will consider whether any serious breaches in Good Clinical 
Practice have occurred which would be reported to the Sponsor who would be responsible for 
informing the MHRA. 
Although there may be some overlap in content, this trial monitoring report should not be 
confused with reports which are prepared by the trial statistician and presented to the 
IDSMC. The IDSMC reports are usually for review only by the IDSMC since they often 
include results of analyses that compare treatments and these interim results could potentially 
introduce bias if released to the trial team. 
Conclusions 
Clinical trials require measures to be taken to assure the quality of data, reliability of results, 
and to protect participants’ rights and safety. Recent developments in the literature by 
international bodies and regulatory agencies [3-6] have supported the need for risk-
proportionate approaches to monitoring. The risk-proportionate approach adopted by the 
CTRC, an active, non-commercial UK clinical trials unit, is described in this paper to aid 
dissemination of methods, promote discussion and contribute to the evidence base that is 
currently lacking. However, further empirical evidence is required to thoroughly evaluate the 
costs, and advantages and disadvantages of alternative methods. Further, more in-depth 
statistical monitoring may be required for the detection of fraud [12], or to supplement simple 
approaches [2] if problems are highlighted. The use of statistical monitoring methods is an 
area of active research and appropriate use of these methods requires careful consideration of 
issues such as multiple testing and trial size. 
Recommendations made by the CTTI project on effective and efficient monitoring as a 
component of quality highlight that ’no single monitoring approach is appropriate or 
necessary in all circumstances’, and that the ’monitoring approach for a given clinical trial 
should be tailored to the needs of that trial and may combine several methods’ [3]. These 
points, along with other recommendations made by CTTI (many of which are reflected in the 
CTRC approach) should be kept in mind when developing the trial monitoring plan in 
conjunction with the trial risk assessment. Furthermore, by publishing the approach taken by 
CTRC we are supporting an ancillary recommendation made by the CTTI project, to ‘Share 
knowledge and experiences’ [3], and we fully encourage further sharing and discussion 
amongst the trials community so that best practices may be established. 
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